115 related articles for article (PubMed ID: 30486699)
21. Topical application of acyclovir-loaded microparticles: quantification of the drug in porcine skin layers.
de Jalón EG; Blanco-Príeto MJ; Ygartua P; Santoyo S
J Control Release; 2001 Jul; 75(1-2):191-7. PubMed ID: 11451509
[TBL] [Abstract][Full Text] [Related]
22. Acyclovir concentrations in the skin of humans after a single oral dose assessed by in vivo cutaneous microdialysis.
Farfal S; Klimowicz A; Bielecka-Grzela S
Skin Res Technol; 2006 Nov; 12(4):228-34. PubMed ID: 17026652
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of skin penetration of topically applied drugs in humans by cutaneous microdialysis: acyclovir vs. salicylic acid.
Klimowicz A; Farfał S; Bielecka-Grzela S
J Clin Pharm Ther; 2007 Apr; 32(2):143-8. PubMed ID: 17381664
[TBL] [Abstract][Full Text] [Related]
24. Apigenin, a novel candidate involving herb-drug interaction (HDI), interacts with organic anion transporter 1 (OAT1).
Wu T; Li H; Chen J; Cao Y; Fu W; Zhou P; Pang J
Pharmacol Rep; 2017 Dec; 69(6):1254-1262. PubMed ID: 29128807
[TBL] [Abstract][Full Text] [Related]
25. Toxic effect of concomitant administration of cyclosporin A and acyclovir on renal function and morphology in rats.
Hannemann J; Wunderle W; Yousif T; Krüger S; Baumann K
Arch Toxicol; 1997; 71(9):556-62. PubMed ID: 9285038
[TBL] [Abstract][Full Text] [Related]
26. Synergistic penetration of ethosomes and lipophilic prodrug on the transdermal delivery of acyclovir.
Zhou Y; Wei YH; Zhang GQ; Wu XA
Arch Pharm Res; 2010 Apr; 33(4):567-74. PubMed ID: 20422366
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of intravenous acyclovir, zidovudine, and acyclovir-zidovudine in pregnant rats.
Brown SD; Bartlett MG; White CA
Antimicrob Agents Chemother; 2003 Mar; 47(3):991-6. PubMed ID: 12604532
[TBL] [Abstract][Full Text] [Related]
28. Critical Review of Synthesis, Toxicology and Detection of Acyclovir.
Wei YP; Yao LY; Wu YY; Liu X; Peng LH; Tian YL; Ding JH; Li KH; He QG
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770975
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and bioavailability of sustained release and conventional formulation of acyclovir.
Zhang JH; Zhu JB; Chen XJ; Zhao R; Gang YY; Wu ZH; Cheng K; Xu XY
Eur J Drug Metab Pharmacokinet; 2001; 26(3):145-8. PubMed ID: 11695713
[TBL] [Abstract][Full Text] [Related]
30. Effect of Azone upon the in vivo antiviral efficacy of cidofovir or acyclovir topical formulations in treatment/prevention of cutaneous HSV-1 infections and its correlation with skin target site free drug concentration in hairless mice.
Afouna MI; Fincher TK; Zaghloul AA; Reddy IK
Int J Pharm; 2003 Mar; 253(1-2):159-68. PubMed ID: 12593946
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of valacyclovir in the adult horse.
Maxwell LK; Bentz BG; Bourne DW; Erkert RS
J Vet Pharmacol Ther; 2008 Aug; 31(4):312-20. PubMed ID: 18638291
[TBL] [Abstract][Full Text] [Related]
32. Topical bioequivalence of acyclovir creams using dermal microdialysis in pigs: a new model to evaluate bioequivalence for topical formulations.
Wei H; Wang S; Xu F; Xu L; Zheng J; Chen Y
Drug Dev Ind Pharm; 2012 Jul; 38(7):785-91. PubMed ID: 22014338
[TBL] [Abstract][Full Text] [Related]
33. Preclinical toxicology studies with acyclovir: teratologic, reproductive and neonatal tests.
Moore HL; Szczech GM; Rodwell DE; Kapp RW; de Miranda P; Tucker WE
Fundam Appl Toxicol; 1983; 3(6):560-8. PubMed ID: 6662297
[TBL] [Abstract][Full Text] [Related]
34. In vitro lymphotoxicity and selective T cell immunotoxicity of high doses of acyclovir and its derivatives in mice.
Poluektova L; Krzystyniak K; Desjardins R; Flipo D; Fournier M
Int J Immunopharmacol; 1996; 18(6-7):429-38. PubMed ID: 9024946
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of microporous polycaprolactone matrices for controlled delivery of antiviral microbicides to the female genital tract.
Asvadi NH; Dang NT; Davis-Poynter N; Coombes AG
J Mater Sci Mater Med; 2013 Dec; 24(12):2719-27. PubMed ID: 23892484
[TBL] [Abstract][Full Text] [Related]
36. [Acyclovir encephalopathy in a peritoneal dialysis patient despite adjusting the dose of oral acyclovir: a case report].
Kawabe Matsukawa M; Suzuki Y; Ikuma D; Suwabe T; Uesaka Y; Sugimoto I
Rinsho Shinkeigaku; 2019 Dec; 59(12):834-839. PubMed ID: 31761838
[TBL] [Abstract][Full Text] [Related]
37. Effect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit cornea.
Majumdar S; Hippalgaonkar K; Repka MA
Int J Pharm; 2008 Feb; 348(1-2):175-8. PubMed ID: 17897799
[TBL] [Abstract][Full Text] [Related]
38. Assessment of correlation between skin target site free drug concentration and the in vivo topical antiviral efficacy in hairless mice for (E)-5-(2-bromovinyl)-2'-deoxyuridine and acyclovir formulations.
Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; De Clercq E; El-Shattawy HH
J Pharm Sci; 1998 Aug; 87(8):917-21. PubMed ID: 9687333
[TBL] [Abstract][Full Text] [Related]
39. Studies on acyclovir-dextran conjugate: synthesis and pharmacokinetics.
Tu J; Zhong S; Li P
Drug Dev Ind Pharm; 2004; 30(9):959-65. PubMed ID: 15554220
[TBL] [Abstract][Full Text] [Related]
40. Nephrotoxicity of acyclovir and ganciclovir in rats: evaluation of glomerular hemodynamics.
Dos Santos Mde F; Dos Santos OF; Boim MA; Razvickas CV; de Moura LA; Ajzen H; Schor N
J Am Soc Nephrol; 1997 Mar; 8(3):361-7. PubMed ID: 9071704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
